IXC Invex Therapeutics Ltd
—Mkt Cap: —P/E: —1d ago
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neu…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value2.68M USD
Revenue (TTM)32.36K USD
Gross Profit32.36K USD
Net Income (TTM)-329.56K USD
Revenue/Share0.0010 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000048621
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue82.75
P/S168.52
P/B2.02
EPS (TTM)-0.02
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-1397.89%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-9.09%
ROA-8.72%
Growth
Revenue Growth-79.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-939.08K USD
CapEx (TTM)—
FCF Margin-2045.14%
FCF Yield—
Net Debt-2.78M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio26.48
Quick Ratio26.48
Book Value/Sh0.05 AUD
Cash/Share0.05 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 8, 2023
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.75.15M
Float46.58M
Insiders63.93%
Institutions0.00%
Technical
SMA 500.1132 AUD
SMA 2000.1128 AUD
Beta0.52
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)31.96K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—